RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects
RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects
Recruiting · NCT05943379 · Registry updated 2023-07-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Non-Muscle Invasive Bladder Neoplasms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, neoplasm, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Recruiting | Phase 2 | 2023-07-13 | NCT05943379 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| RemeGen Co., Ltd. | 36 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Peking University First Hosptital | Beijing | China | 1 |